NCT07391215 2026-02-05
5G-PEARL
Institute of Cancer Research, United Kingdom
Phase 1/2 Recruiting
Clinical Trials
8 trialsNCT03765983 2026-01-22
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT05009992 2025-12-17
PNOC022
University of California, San Francisco
Phase 2 Recruiting
NCT03970447 2025-09-09
GBM AGILE
Global Coalition for Adaptive Research
Phase 2/3 Recruiting
NCT04192981 2025-04-17
GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT03522298 2025-03-24
Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma
Kazia Therapeutics Limited
Phase 2 Completed
NCT03696355 2023-01-18
Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas
St. Jude Children's Research Hospital
Phase 1 Completed
NCT01547546 2016-11-02
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
Genentech, Inc.
Phase 1 Completed